Cogent Biosciences, Inc. Variable Lease, Cost
Cogent Biosciences, Inc. (COGT) reported Variable Lease, Cost of $714.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-17
- Cogent Biosciences, Inc. variable lease, cost for the quarter ending 2022-12-31 was $255.00K, a 22.01% increase year-over-year.
- Cogent Biosciences, Inc. variable lease, cost for the quarter ending 2022-09-30 was $258.00K, a 21.13% increase year-over-year.
- Cogent Biosciences, Inc. variable lease, cost for the quarter ending 2022-06-30 was $217.00K, a 3.56% decline year-over-year.
- Cogent Biosciences, Inc. variable lease, cost for the quarter ending 2022-03-31 was $261.00K, a 46.63% increase year-over-year.
- Cogent Biosciences, Inc. variable lease, cost for fiscal 2025 was $714.00K, a 11.52% decline from fiscal 2024.
- Cogent Biosciences, Inc. variable lease, cost for fiscal 2024 was $807.00K, a 17.47% increase from fiscal 2023.
- Cogent Biosciences, Inc. variable lease, cost for fiscal 2023 was $687.00K, a 30.68% decline from fiscal 2022.
- Cogent Biosciences, Inc. variable lease, cost for fiscal 2022 was $991.00K, a 20.12% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $714.00K 10-K · filed 2026-02-17 | |||
| 2024-12-31 | $807.00K 10-K · filed 2026-02-17 | |||
| 2023-12-31 | $687.00K 10-K · filed 2026-02-17 | |||
| 2022-12-31 | $255.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $513.00K derived: sum of 2 quarters · filed 2025-02-25 | $730.00K derived: sum of 3 quarters · filed 2025-02-25 | $991.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | $258.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $475.00K derived: sum of 2 quarters · filed 2022-11-14 | $736.00K 10-Q · filed 2022-11-14 | $945.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $217.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $478.00K 10-Q · filed 2022-08-09 | $687.00K derived: sum of 3 quarters · filed 2024-02-26 | $900.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $261.00K 10-Q · filed 2022-05-10 | $470.00K derived: sum of 2 quarters · filed 2024-02-26 | $683.00K derived: sum of 3 quarters · filed 2024-02-26 | $908.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $209.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $422.00K derived: sum of 2 quarters · filed 2024-02-26 | $647.00K derived: sum of 3 quarters · filed 2024-02-26 | $825.00K 10-K · filed 2024-02-26 |
| 2021-09-30 | $213.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $438.00K derived: sum of 2 quarters · filed 2021-11-10 | $616.00K 10-Q · filed 2021-11-10 | $813.00K derived: sum of 4 quarters · filed 2022-03-15 |
| 2021-06-30 | $225.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $403.00K 10-Q · filed 2021-08-16 | $600.00K derived: sum of 3 quarters · filed 2022-03-15 | |
| 2021-03-31 | $178.00K 10-Q · filed 2021-05-12 | $375.00K derived: sum of 2 quarters · filed 2022-03-15 | ||
| 2020-12-31 | $197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $890.00K 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $693.00K 10-Q · filed 2020-11-09 | |||
| 2019-12-31 | $240.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $494.00K derived: sum of 2 quarters · filed 2021-03-16 | $770.00K derived: sum of 3 quarters · filed 2021-03-16 | $1.07M 10-K · filed 2021-03-16 |
| 2019-09-30 | $254.00K 10-Q · filed 2019-11-12 | $530.00K derived: sum of 2 quarters · filed 2019-11-12 | $835.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $276.00K 10-Q · filed 2019-08-12 | $581.00K 10-Q · filed 2019-08-12 | ||
| 2019-03-31 | $305.00K 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |